Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates is a research paper published in FEBS Open Bio (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH Office of the Director
Grant: R03OD030604
National Institute of General Medical Sciences
Grant: 5T32GM008361‐31
National Human Genome Research Institute
Grant: R00HG009678
NIGMS NIH HHS
Grant: T32 GM008361
NIDDK NIH HHS
Grant: U2C DK133422
NIGMS NIH HHS
Grant: 5T32GM008361-31
NIDDK NIH HHS
Grant: TL1 DK139566
National Institutes of Health
Grant: 1R03OD030604-01
Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing
National Institutes of Health
Grant: 5T32GM008361-26
Medical Scientist Training Program
National Institutes of Health
Grant: 5R00HG009678-04
Integrating multidimensional genomic data to discover clinically-relevant predictive models
American Cancer Society
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals